Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$642 Mln
Revenue (TTM)
$275 Mln
Net Profit (TTM)
$0 Mln
ROE
-9.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
53.7
Industry P/E
28.33
EV/EBITDA
-21.5
Div. Yield
0 %
Debt to Equity
-18.4
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
64,475,600
CFO
$-315.78 Mln
EBITDA
$-413.67 Mln
Net Profit
$-538.48 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evolus (EOLS)
| -15.8 | -4.1 | -31.6 | -14.5 | -7.0 | 13.1 | -- |
|
BSE Sensex*
| 4.0 | -1.1 | 8.1 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Evolus (EOLS)
| 4.8 | 40.2 | 15.4 | 93.8 | -72.4 | 2.3 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evolus (EOLS)
|
9.3 | 642.2 | 275.0 | -56.2 | -21.3 | -- | -- | 53.7 |
| 18.1 | 4,870.2 | 459.4 | 206.8 | 25.6 | 68.3 | 24.3 | 13.3 | |
| 29.3 | 3,591.5 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.7 | |
| 102.9 | 5,125.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 94.0 | |
| 55.2 | 10,785.5 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.8 | 1.9 | |
| 40.0 | 7,811.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 71.2 | 7,619.3 | 685.5 | 132.9 | 15.6 | 20.1 | 61.9 | 11.0 | |
| 13.3 | 6,948.1 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.1 | 1.1 | |
| 83.6 | 4,135.0 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.5 | 2.3 | |
| 8.8 | 10,281.4 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the... temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660 Read more
President, CEO & Director
Mr. David Moatazedi
President, CEO & Director
Mr. David Moatazedi
Headquarters
Newport Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Evolus Inc (EOLS) stood at $ 270 Mln as on 31-Mar-25
The share price of Evolus Inc (EOLS) is $9.30 (NASDAQ) as of 18-Jun-2025 16:00 EDT. Evolus Inc (EOLS) has given a return of -6.97% in the last 3 years.
Evolus Inc (EOLS) has a market capitalisation of $ 642 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Evolus Inc (EOLS) is 53.71 times as on 18-Jun-2025, a 1012% premium to its peers’ median range of 4.83 times.
Since, TTM earnings of Evolus Inc (EOLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Evolus Inc (EOLS) and enter the required number of quantities and click on buy to purchase the shares of Evolus Inc (EOLS).
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660
The CEO & director of Mr. David Moatazedi. is Evolus Inc (EOLS), and CFO & Sr. VP is Mr. David Moatazedi.
There is no promoter pledging in Evolus Inc (EOLS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,096
|
|
|
1,054
|
|
|
755
|
|
|
741
|
|
|
709
|
|
|
532
|
|
|
522
|
|
|
421
|
|
|
386
|
| Evolus Inc. (EOLS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-21.29
|
|
Net Margin(%)
|
-20.44
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Evolus Inc (EOLS) was $0 Mln.
$0.05
(
